Participants in the Solicitation
SGX and its directors and executive officers may be deemed to be participants in the solicitation of proxies from SGX stockholders in connection with the merger. Certain directors and executive officers of SGX may have direct or indirect interests in the merger due to, among other things, securities holdings, pre-existing or future indemnification arrangements, vesting of equity awards, or rights to severance payments in connection with the merger. Additional information regarding the directors and executive officers of SGX and their interests in the merger is contained in the definitive proxy statement that SGX filed with the SEC.
Forward Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include, but are
not limited to, statements related to research and development programs,
the proposed merger transaction, including whether the merger transaction
will be approved by SGX's stockholders, whether the other conditions to
closing of the proposed transaction will be met and if any of the potential
benefits of the proposed merger will be realized, the potential of the
Company's inhibitors as treatments for certain cancers, and the ability to
discover, develop, build a pipeline of and commercialize cancer
|SOURCE SGX Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved